Tenderwize
Back to tender search

Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 377 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim

50/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

40 / 100

Risk factors

The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...

Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Conclusion of pharmaceutical discount agreements for Pegfilgrastim under §130a(8) SGB V.
  • Open-House procedure: any eligible pharmaceutical entrepreneur can participate.
Show full summary

Open House procedure for concluding discount agreements (Rabattverträge) under §130a(8) SGB V for the active substance Pegfilgrastim. Any qualified pharmaceutical entrepreneur can join during the contract period (01.09.2025 – 31.08.2027). No exclusivity, no negotiated terms; uniform conditions apply.

Risks

The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...

Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur according to §4(18) AMG regarding the offered medicinal product.
  • Must have a valid marketing authorization for the drug (§21 AMG) or be otherwise entitled to market it.
  • Seat must be in Germany, another EU member state, or an EEA state.

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim

Conclusion of discount agreements for the active substance Pegfilgrastim via Open-House procedure. Open to all eligible pharmaceutical entrepreneurs during the contract period.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Aug 2025 - Aug 2027

Category

Pharmaceutical products

Deadline

Deadline Aug 30, 2027

Procurement Details

Publication date
16 Jul 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
468072-2025

Documents (1)

Similar tenders